Osteoarthritis – Epidemiology – Epidemiology – Osteoarthritis – Emerging Markets
Clarivate Epidemiology’s coverage of osteoarthritis (OA) comprises epidemiological estimates of key patient populations in 14 mature and emerging pharmaceutical markets worldwide. We report the diagnosed prevalence of OA for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.
Clarivate Epidemiology’s OA forecast will answer the following questions:
- How will changes in the levels of exposure to known risk or protective factors affect the number of people living with a diagnosis of OA?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of OA over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, Clarivate Epidemiology forecasts one OA patient populations, as follows:
- Diagnosed lifetime prevalent cases.
Note: Coverage may vary by country.
